Related Experiment Video
Updated: Jun 26, 2026
09:58
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
Why lipids are important for Alzheimer disease?
Veronica Hirsch-Reinshagen1, Braydon L Burgess, Cheryl L Wellington
1Department of Pathology and Laboratory Medicine, University of British Columbia, 980 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada.
Molecular and Cellular Biochemistry
|January 1, 2009
Summary
Dysregulated lipid metabolism, particularly involving apolipoprotein E (apoE) and ABCA1, is implicated in Alzheimer's disease (AD) pathogenesis. Enhancing apoE lipidation via ABCA1 may offer a therapeutic strategy for AD.
Area of Science:
- Neuroscience
- Metabolic Disorders
- Genetics
Background:
- Alzheimer's disease (AD) pathogenesis is increasingly linked to lipid metabolism dysregulation.
- Elevated cholesterol and apolipoprotein E (apoE) are associated with increased AD risk.
- The precise role of apoE in AD pathogenesis requires further elucidation.
Purpose of the Study:
- To investigate the role of the cholesterol transporter ABCA1 in regulating apoE levels and lipidation in the brain.
- To determine how ABCA1-mediated apoE lipidation impacts amyloid pathology in Alzheimer's disease.
Main Methods:
- Investigated the relationship between ABCA1 deficiency and apoE levels/lipidation in the brain.
- Assessed the impact of altered apoE lipidation on amyloid burden in AD mouse models.
- Examined the effects of ABCA1 overexpression on apoE lipidation and amyloid plaque formation.
Main Results:
- ABCA1 deficiency drastically reduces brain apoE levels and impairs its lipidation.
- Poorly lipidated apoE exacerbates amyloid pathology in AD mouse models.
- Increased ABCA1 expression enhances apoE lipidation and significantly reduces amyloid plaques.
Conclusions:
- ABCA1 is a critical regulator of apoE lipidation, influencing Alzheimer's disease pathology.
- The lipid-binding capacity of apoE is a key mechanism in AD pathogenesis.
- Enhancing apoE lipidation through ABCA1 modulation presents a potential therapeutic avenue for Alzheimer's disease.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...